Company profile

Ripple Therapeutics

Drug deliveryChallengingFounded 2018

Epidel — biodegradable sustained-release implants for glaucoma and other eye disease.

About

Developing a family of biodegradable, sustained-release drug delivery implants (Epidel platform) for glaucoma and other chronic eye conditions.

HQ: Toronto, Canada

Funding

VC-backed; pursuing financing for Phase 2